Shigella Sonnei OSPC-rDT Conjugate Vaccine

Shigellosis

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Tebipenem Trial in Children With Shigellosis Controlled Human Infection Model Challenge/Rechallenge Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Therapeutic Induction of Endogenous Antibiotics A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Shigella Sonnei OSPC-rDT Conjugate Vaccine Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection